Economic Burden of SARS-CoV-2 Patients with Multi-Morbidity: A Systematic Review Protocol

Amirah Azzeri, Mohd Noor Afiq Ramlee, Mohd Iqbal Mohd Noor, Mohd Hafiz Jaafar, Thinni Nurul Rochmah and Maznah Dahlui
Additional contact information
Amirah Azzeri: Faculty of Medicine & Health Science, Universiti Sains Islam Malaysia (USIM), Persiaran Ilmu, Bandar Baru Nilai, Nilai 71800, Negeri Sembilan, Malaysia
Mohd Noor Afiq Ramlee: Faculty of Medicine & Health Science, Universiti Sains Islam Malaysia (USIM), Persiaran Ilmu, Bandar Baru Nilai, Nilai 71800, Negeri Sembilan, Malaysia
Mohd Iqbal Mohd Noor: Faculty of Business Management, Universiti Teknologi MARA (UiTM) (Pahang), Raub 27600, Pahang, Malaysia
Mohd Hafiz Jaafar: Faculty of Medicine & Health Science, Universiti Sains Islam Malaysia (USIM), Persiaran Ilmu, Bandar Baru Nilai, Nilai 71800, Negeri Sembilan, Malaysia
Thinni Nurul Rochmah: Department of Health Administration and Policy, Faculty of Public Health, Universitas Airlangga, Surabaya 60115, Jawa Timur, Indonesia
Maznah Dahlui: Department of Research Development and Innovation, University of Malaya Medical Centre (UMMC), Lembah Pantai, Kuala Lumpur 59100, Malaysia

IJERPH, 2022, vol. 19, issue 20, 1-11

Abstract: Economic burden issues in SARS-CoV-2 patients with underlying co-morbidities are enormous resources for patient treatment and management. The uncertainty costs for clinical management render the healthcare system catatonic and incurs deficits in national annual budgets. This article focuses on systematic steps towards selecting and evaluating literature to uncover gaps and ways to help healthcare stakeholders optimize resources in treating and managing COVID-19 patients with multi-morbidity. A systematic review of all COVID-19 treatment procedures with co-morbidities or multi-morbidity for the period from 2019 to 2022 was conducted. The search includes studies describing treatment costs associated with multi- or co-morbidity cases for infected patients and, if concurrently reported, determining recurring expenses. Study selection will follow the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Galbraith plots and I 2 statistics will be deployed to assess heterogeneity and to identify potential sources. A backward elimination process will be applied in the regression modelling procedure. Based on the number of studies retrieved and their sample size, the subgroup analysis will be stratified on participant disease category, associated total costs, and degree of freedom in cost estimation. These studies were registered in the PROSPERO registry (ID: CRD42022323071).

Keywords: COVID-19; economic burden; comorbidity; cardio/cerebrovascular; diabetes; hypertension; respiratory diseases (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2022
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.mdpi.com/1660-4601/19/20/13157/pdf (application/pdf)
https://www.mdpi.com/1660-4601/19/20/13157/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:19:y:2022:i:20:p:13157-:d:940786

Access Statistics for this article

IJERPH is currently edited by Ms. Jenna Liu

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().